Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1982 Jul;46(1):101–108. doi: 10.1038/bjc.1982.171

Radiation and nitroimidazoles in supratentorial high grade gliomas: a second clinical trial.

R Urtasun, M L Feldstein, J Partington, H Tanasichuk, J D Miller, D B Russell, O Agboola, B Mielke
PMCID: PMC2011055  PMID: 6285947

Abstract

As a continuation of a previous controlled trial using "high-dose" metronidazole as a specific sensitizer of hypoxic cells, we used a more efficient nitroimidazole derivative (misonidazole, MISO) in combination with higher doses of radiation in patients with supratentorial high-grade astrocytomas. Sixty-six patients were stratified according to functional level and histological grading, and randomly allocated within 2 weeks of operation of 1 of 3 therapeutic groups: 1, conventional radiation alone; 2, large fractions of radiation with high-dose metronidazole; and 3, radiation as in Group 2 but with equitoxic doses of MISO. We examined survival as the principal end-point of the study. Neither by increasing the dose of radiation over the previous study, nor by using a more efficient sensitizer, were we able to improve survival over the current conventional daily fractionated radiation.

Full text

PDF
101

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asquith J. C., Foster J. L., Willson R. L., Ings R., McFadzean J. A. Metronidazole ("Flagyl"). A radiosensitizer of hypoxic cells. Br J Radiol. 1974 Aug;47(560):474–481. doi: 10.1259/0007-1285-47-560-474. [DOI] [PubMed] [Google Scholar]
  2. Bleehen N. M. The Cambridge glioma trial of misonidazole and radiation therapy with associated pharmacokinetic studies. Cancer Clin Trials. 1980 Fall;3(3):267–273. [PubMed] [Google Scholar]
  3. Chapman J. D., Reuvers A. P., Borsa J. Effectiveness of nitrofuran derivatives in sensitizing hypoxic mammalian cells to x rays. Br J Radiol. 1973 Aug;46(548):623–630. doi: 10.1259/0007-1285-46-548-623. [DOI] [PubMed] [Google Scholar]
  4. Denekamp J., Harris S. R. Tests of two electron-affinic radiosensitizers in vivo using regrowth of an experimental carcinoma. Radiat Res. 1975 Feb;61(2):191–203. [PubMed] [Google Scholar]
  5. Deutsch G., Foster J. L., McFadzean J. A., Parnell M. Human studies with "high dose" metronidazole: a non-toxic radiosensitizer of hypoxic cells. Br J Cancer. 1975 Jan;31(1):75–80. doi: 10.1038/bjc.1975.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Disch S., Saunders M. I., Anderson P., Urtasun R. C., Karcher K. H., Kogelnik H. D., Bleehen N., Phillips T. L., Wasserman T. H. The neurotoxicity of misonidazole: pooling of data from five centres. Br J Radiol. 1978 Dec;51(612):1023–1024. doi: 10.1259/0007-1285-51-612-1023. [DOI] [PubMed] [Google Scholar]
  7. Edwards M. S., Levin V. A., Wilson C. B. Brain tumor chemotherapy: an evaluation of agents in current use for phase II and III trials. Cancer Treat Rep. 1980;64(12):1179–1205. [PubMed] [Google Scholar]
  8. Frytak S., Moertel C. H., Childs D. S. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med. 1978 Mar;88(3):361–362. doi: 10.7326/0003-4819-88-3-361. [DOI] [PubMed] [Google Scholar]
  9. Hoshino T., Barker M., Wilson C. B., Boldrey E. B., Fewer D. Cell kinetics of human gliomas. J Neurosurg. 1972 Jul;37(1):15–26. doi: 10.3171/jns.1972.37.1.0015. [DOI] [PubMed] [Google Scholar]
  10. Kogelnik H. D. Clinical experience with misonidazole: high dose fractions versus daily low doses. Cancer Clin Trials. 1980 Summer;3(2):179–186. [PubMed] [Google Scholar]
  11. Letter: Metronidazole as a radiosensitizer. N Engl J Med. 1976 Oct 14;295(16):901–902. doi: 10.1056/NEJM197610142951619. [DOI] [PubMed] [Google Scholar]
  12. Thomas G. M., Rauth A. M., Bush R. S., Black B. E., Cummings B. J. A toxicity study of daily dose metronidazole with pelvic irradiation. Cancer Clin Trials. 1980 Fall;3(3):223–230. [PubMed] [Google Scholar]
  13. Urtasun R. C., Chapman J. D., Band P., Rabin H. R., Fryer C. G., Sturmwind J. Phase 1 study of high-dose metronidazole: a specific in vivo and in vitro radiosensitizer of hypoxic cells. Radiology. 1975 Oct;117(1):129–133. doi: 10.1148/117.1.129. [DOI] [PubMed] [Google Scholar]
  14. Urtasun R. C., Chapman J. D., Feldstein M. L., Band R. P., Rabin H. R., Wilson A. F., Marynowski B., Starreveld E., Shnitka T. Peripheral neuropathy related to misonidazole: incidence and pathology. Br J Cancer Suppl. 1978 Jun;3:271–275. [PMC free article] [PubMed] [Google Scholar]
  15. Urtasun R. C., Sturmwind J., Rabin H., Band P. R., Chapman J. D. Letter: "High-dose" metronidazole: a preliminary pharmacological study prior to its investigational use in clinical radiotherapy trials. Br J Radiol. 1974 May;47(557):297–299. doi: 10.1259/0007-1285-47-557-297-c. [DOI] [PubMed] [Google Scholar]
  16. Urtasun R., Band P., Chapman J. D., Feldstein M. L., Mielke B., Fryer C. Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med. 1976 Jun 17;294(25):1364–1367. doi: 10.1056/NEJM197606172942503. [DOI] [PubMed] [Google Scholar]
  17. Walker M. D., Alexander E., Jr, Hunt W. E., MacCarty C. S., Mahaley M. S., Jr, Mealey J., Jr, Norrell H. A., Owens G., Ransohoff J., Wilson C. B. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978 Sep;49(3):333–343. doi: 10.3171/jns.1978.49.3.0333. [DOI] [PubMed] [Google Scholar]
  18. Walker M. D., Strike T. A. Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs. Cancer Clin Trials. 1980 Summer;3(2):105–109. [PubMed] [Google Scholar]
  19. Wasserman T. H., Phillips T. L., Johnson R. J., Gomer C. J., Lawrence G. A., Sadee W., Marques R. A., Levin V. A., VanRaalte G. Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys. 1979 Jun;5(6):775–786. doi: 10.1016/0360-3016(79)90061-0. [DOI] [PubMed] [Google Scholar]
  20. Wasserman T. H., Phillips T. L., Van Raalte G., Urtasun R., Partington J., Koziol D., Schwade J. G., Gangji D., Strong J. M. The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone. Br J Radiol. 1980 Feb;53(626):172–173. doi: 10.1259/0007-1285-53-626-172. [DOI] [PubMed] [Google Scholar]
  21. Workman P. Drug interactions with misonidazole: effects of dexamethasone and its derivatives on the pharmacokinetics and toxicity of misonidazole in mice. Biochem Pharmacol. 1980 Oct 15;29(20):2769–2776. doi: 10.1016/0006-2952(80)90010-6. [DOI] [PubMed] [Google Scholar]
  22. Workman P., Little C. J., Marten T. R., Dale A. D., Ruane R. J., Flockhart I. R., Bleehen N. M. Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr. 1978 May 1;145(3):507–512. doi: 10.1016/s0378-4347(00)81386-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES